Top Shipping Companies To Buy For 2015

Top Shipping Companies To Buy For 2015: Catalyst Pharmaceutical Partners Inc.(CPRX)

Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. It is evaluating its lead product candidate, CPP-109, a GABA aminotransferase inhibitor candidate, which is under Phase II(b) clinical trial for the treatment of cocaine addiction, as well as focuses on evaluating CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. The company is also developing CPP-115, a GABA aminotransferase inhibitor for various indications, including drug addiction, epilepsy, and for other selected central nervous disease indications. It has license agreements with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions, and obsessive-compulsive disorders; and with Northwestern University to commercialize GABA aminotransferase inhibitors worldwide, as well as a definitive clinical trial agreement with the National Institute on Drug Abuse to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109 for the treatment of cocaine addiction. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Advisors' Opinion:

• [By Roberto Pedone]

  Catalyst Pharmaceutical Partners (CPRX) is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock closed flat to $1.87 in Tuesday's trading session.

  Tuesday's Range: $1.78-$1.98
  
  52-Week Range: $0.41-$3.65
  
  Tuesday's Volume: 1.62 million
  
  Three-Month Average Volume: 2.20 million

  From a technical perspectiv! e, CPRX closed off its intraday low of $1.78 to $1.87 with lighter-than-average volume. This stock has been uptrending for the last few weeks, with shares moving higher from its low of $1.29 to its recent high of $2.07. During that move, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CPRX within range of triggering a near-term breakout trade. That trade will hit if CPRX manages to take out some near-term overhead resistance levels at $2.07 to its 50-day moving average of $2.16 with high volume.

  Traders should now look for long-biased trades in CPRX as long as it's trending above some near-term support at $1.63 and then once it sustains a move or close above those breakout levels with volume that's near or above 2.20 million shares. If that breakout hits soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65.

• [By Roberto Pedone]

  One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Catalyst Pharmaceutical Partners (CPRX), which is focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. This stock has been on fire so far in 2013, with shares up a whopping 364%.

  If you take a look at the chart for Catalyst Pharmaceutical Partners, you'll notice that this stock has been uptrending strong for the last month, with shares soaring higher from its low of $1.29 to its intraday high of $2.09 a share. During that uptrend, shares of CPRX have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed share of CPRX within range of triggering a big breakout trade.!

  ! Traders should now look for long-biased trades in CPRX if it manages to break out above its 50-day moving average of $2.11 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 2.21 million shares. If that breakout triggers soon, then CPRX will set up to re-test or possibly take out its next major overhead resistance levels at $2.87 to $3 a share. Any high-volume move above those levels will then give CPRX a chance to re-test its 52-week high at $3.65 a share.

  Traders can look to buy CPRX off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.65 to $1.63 a share. One can also buy CPRX off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Paul Ausick]

  Stocks on the move: Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) is up about 40% at $1.98 after its firdapse drug treatment for certain kinds of muscle weakness was designated a breakthrough therapy by the FDA. Food maker Dean Foods Inc. (NYSE: DF) held a 1-for-2 reverse stock split this morning and the shares are up about 95%, as might be expected.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-shipping-companies-to-buy-for-2015.html